Comparison 19. Antacids versus sucralfate.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinically important upper GI bleeding	16	1772	Risk Ratio (M‐H, Fixed, 95% CI)	1.00 [0.72, 1.39]
1.1 Antacids vs sucralfate	15	1705	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.69, 1.35]
1.2 Antacid + pirenzepine vs sucralfate + pirenzepine	1	67	Risk Ratio (M‐H, Fixed, 95% CI)	5.15 [0.26, 103.33]
2 Nosocomial pneumonia	7		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 Antacids vs sucralfate	7	996	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.84, 1.30]
3 All‐cause mortality in ICU	11	1249	Risk Ratio (M‐H, Fixed, 95% CI)	1.15 [0.93, 1.40]
3.1 Antacid vs sucralfate	10	1182	Risk Ratio (M‐H, Fixed, 95% CI)	1.15 [0.94, 1.41]
3.2 Antacid + pirenzepine vs sucralfate + pirenzepine	1	67	Risk Ratio (M‐H, Fixed, 95% CI)	1.03 [0.28, 3.78]
4 All‐cause mortality in hospital	3	450	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.69, 1.39]
5 Duration of ICU stay	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
5.1 Antacids vs sucralfate	2	227	Mean Difference (IV, Fixed, 95% CI)	‐2.50 [‐6.61, 1.61]
6 Duration of intubation	4		Std. Mean Difference (IV, Fixed, 95% CI)	Subtotals only
6.1 Antacids vs sucralfate	4	281	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.18 [‐0.41, 0.06]
7 Number of participants requiring blood transfusion	6	667	Risk Ratio (M‐H, Fixed, 95% CI)	0.73 [0.40, 1.34]
8 Adverse events of interventions	9		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
8.1 Diarrhoea	6	599	Risk Ratio (M‐H, Fixed, 95% CI)	12.40 [3.88, 39.64]
8.2 Hypermagnesaemia	4	317	Risk Ratio (M‐H, Fixed, 95% CI)	4.72 [1.24, 17.95]
8.3 Nausea and vomiting	3	223	Risk Ratio (M‐H, Fixed, 95% CI)	0.63 [0.28, 1.41]
8.4 Thrombocytopaenia	1	38	Risk Ratio (M‐H, Fixed, 95% CI)	5.0 [0.26, 97.70]
8.5 Severe alkalosis	1	100	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.13, 71.92]
8.6 Allergic reactions	1	100	Risk Ratio (M‐H, Fixed, 95% CI)	0.2 [0.01, 4.06]